Combined Effect of Hsp90 Inhibitor Geldanamycin and Parthenolide via Reactive Oxygen Species-Mediated Apoptotic Process on Epithelial Ovarian Cancer Cells

Basic and Clinical Pharmacology and Toxicology

Volumn 111, Issue 3, 2012, Pages 173-181

  Lee, Chung S ^a   Kim, Yun J ^a   Lee, Seon A ^a   Myung, Soon C ^b   Kim, Wonyong ^a  

^a Chung Ang University   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CYTOCHROME C; GELDANAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PARTHENOLIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SURVIVIN;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SECRETION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BENZOQUINONES; BLOTTING, WESTERN; CASPASE 3; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROMES C; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MITOCHONDRIA; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; REACTIVE OXYGEN SPECIES; SESQUITERPENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865122055     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2012.00883.x     Document Type: Article

References (40)

1. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14:1169-76.
2. Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Targeting HSP90 for cancer therapy. Br J Cancer 2009;100:1523-9.
3. Young JC, Agashe VR, Siegers K, Harti FU. Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev Mol Cell Biol 2004;5:781-91.
4. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
5. Moser C, Lang SA, Stoeltzing O. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer. Anticancer Res 2009;29:2031-42.
6. Reikvam H, Ersvaer E, Bruserud O. Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia. Curr Cancer Drug Targets 2009;9:761-76.
7. Hwang M, Moretti L, Lu B. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Curr Med Chem 2009;16:3081-92.
8. Fedier A, Stuedii A, Fink D. Presence of MLH1 protein aggravates the potential of the HSP90 inhibitor radicicol to sensitize tumor cells to cisplatin. Int J Oncol 2005;27:1697-705.
9. Ohba S, Hirose Y, Yoshida K, Yazaki T, Kawase T. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells. J Neurosurg 2010;112:33-42.
10. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006;1:S125-35.
11. Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA, Darwiche N. What made sesquiterpene lactones reach cancer clinical trials? Drug Discov Today 2007;15:668-78.
12. Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu JW, et al. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem 2010;285:9792-802.
13. Shah VO, Ferguson JE, Hunsaker LA, Deck LM, Vander Jagt DL. Natural products inhibit LPS-induced activation of pro-inflammatory cytokines in peripheral blood mononuclear cells. Nat Prod Res 2010;24:1177-88.
14. Carlisi D, D'Anneo A, Angileri L, Lauricella M, Emanuele S, Santulli A, et al. Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. J Cell Physiol 2011;226:1632-41.
15. Fang LJ, Shao XT, Wang S, Lu GH, Xu T, Zhou YJ. Sesquiterpene lactone parthenolide markedly enhances sensitivity of human A549 cells to low-dose oxaliplatin via inhibition of NF-kappaB activation and induction of apoptosis. Planta Med 2010;76:258-64.
16. Sohma I, Fujiwara Y, Sugita Y, Yoshioka A, Shirakawa M, Moon JH, et al. Parthenolide, an NF-κB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. Cancer Genomics Proteomics 2011;8:39-47.
17. Zanotto-Filho A, Braganhol E, Schröder R, de Souza LH, Dalmolin RJ, Pasquali MA, et al. NFκB inhibitors induce cell death in glioblastomas. Biochem Pharmacol 2011;81:412-24.
18. Gao ZW, Zhang DL, Guo CB. Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in in vitro and in vivo human non-small cell lung cancer models. Curr Cancer Drug Targets 2010;10:705-15.
19. Sun Y, St Clair DK, Xu Y, Crooks PA, St Clair WH. A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Cancer Res 2010;70:2880-90.
20. Dai Y, Guzman ML, Chen S, Wang L, Yeung SK, Pei XY, et al. The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br J Haematol 2010;151:70-83.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
22. Andrisano V, Ballardini R, Hrelia P, Cameli N, Tosti A, Gotti R, et al. Studies on the photostability and in vitro phototoxicity of Labetalol. Eur J Pharm Sci 2001;12:495-504.
23. Oberhammer FA, Pavelka M, Sharma S, Tiefenbacher R, Purchio AF, Bursch W, et al. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1. Proc Natl Acad Sci USA 1992;89:5408-12.
24. Wu H, Rao GN, Dai B, Singh P. Autocrine gastrins in colon cancer cells up-regulate cytochrome c oxidase Vb and down-regulate efflux of cytochrome c and activation of caspase-8. J Biol Chem 2000;275:32491-8.
25. Dai Y, Liu M, Tang W, Li Y, Lian J, Lawrence TS, et al. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-κB. BMC Cancer 2009;9:392.
26. Berthier A, Lemaire-Ewing S, Prunet C, Monier S, Athias A, Bessede G, et al. Involvement of a calcium-dependent dephosphorylation of BAD associated with the localization of Trpc-1 within lipid rafts in 7-ketocholesterol-induced THP-1 cell apoptosis. Cell Death Differ 2004;11:897-905.
27. Fu W, Luo H, Parthasarathy S, Mattson MP. Catecholamines potentiate amyloid β-peptide neurotoxicity: involvement of oxidative stress, mitochondrial dysfunction, and perturbed calcium homeostasis. Neurobiol Dis 1998;5:229-43.
28. Sano M. Radicicol and geldanamycin prevents neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons. Neuropharmacology 2001;40:947-53.
29. Sohn MJ, Noh HJ, Yoo ID, Kim WG. Protective effect of radicicol against LPS/IFN-γ-induced neuronal cell death in rat cortical neuron-glia cultures. Life Sci 2007;80:1706-12.
30. Camins A, Pallas M, Silvestre JS. Apoptotic mechanisms involved in neurodegenerative diseases: experimental and therapeutic approaches. Methods Find Exp Clin Pharmacol 2008;30:43-65.
31. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 2003;4:721-9.
32. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005;4:139-63.
33. Kim R, Emi M, Tanabe K. Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol 2006;57:545-53.
34. Borutaite V. Mitochondria as decision-makers in cell death. Environ Mol Mutagen 2010;51:406-16.
35. Wiman KG. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 2006;13:921-6.
36. Chen F, Wang W, El-Deiry WS. Current strategies to target p53 in cancer. Biochem Pharmacol 2010;80:724-30.
37. Zhivotovsky B, Orrenius S. Cell death mechanisms: cross-talk and role in disease. Exp Cell Res 2010;316:1374-83.
38. Mignotte B, Vayssière JL. Mitochondria and apoptosis. Eur J Biochem 1998;252:1-15.
39. Ott M, Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria, oxidative stress and cell death. Apoptosis 2007;12:913-22.
40. Armstrong JS. Mitochondria: a target for cancer therapy. Br J Pharmacol 2006;147:239-48.